This prospective observational study will evaluate the efficacy and safety of first-line Avastin (bevacizumab) in combination with platinum-based chemotherapy in different age groups (\<60, 60-69, 70-79, \>80 years) in patients with inoperable advanced, metastatic or recurrent adenocarcinoma non-small cell lung cancer. Patients will be followed for 18 months from the start of first-line therapy.
Study Type
OBSERVATIONAL
Enrollment
1,107
Universität Leipzig; Medizinische Klinik und Poliklinik I, Abteilung Pneumologie
Leipzig, Germany
Progression-free survival in 4 different age groups (<60, 60-69, 70-79, >/=80 years)
Time frame: approximately 4.5 years
Overall survival in 4 different age groups (<60, 60-69, 70-79, >/=80 years)
Time frame: approximately 4.5 years
Clinical/demographic patient characteristics at initiation of treatment
Time frame: approximately 4.5 years
Avastin treatment schedule in routine clinical practice (dosage/duration)
Time frame: approximately 4 years
Concomitant anti-neoplastic therapy (dosage/duration)
Time frame: approximately 4.5 years
Safety: Incidence of adverse events in 4 different age groups (<60, 60-69, 70-79, >/=80 years)
Time frame: approximately 4.5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.